Polarean Imaging Plc
("Polarean" or the "Company")
Block Listing Six Monthly Return
Polarean Imaging plc (AIM: POLX a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of lung function, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
| Name of applicant: | Polarean Imaging Plc | ||||
| Name of scheme: | Polarean Share Option Plan | ||||
| Number and class of securities originally admitted: | 8,000,000 ordinary shares of £0.00037 each | ||||
| Date of admission: | 29 July 2021 | ||||
| Period of return: | From: | 27 January 2024 | To: | 26 July 2024 | |
| Balance of unallotted securities under scheme(s) from previous return: | 1,224,573 | ||||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0
| ||||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 415,656
| ||||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 808,917 | ||||
| Total number of securities in issue at the end of the period | 1,207,032,781 | ||||
| | | | | ||
| Name of contact: | Charles F. Osborne, Jr., Chief Financial Officer |
| Telephone number of contact: | + 44 (0)20 7933 8780 or polarean@walbrookpr.com |
Enquiries:
| Polarean Imaging plc | |||||
| Christopher von Jako, Chief Executive Officer | Via Walbrook PR | ||||
| Charles Osborne, Chief Financial Officer |
| ||||
| |
| ||||
| Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) | +44 (0)20 7710 7600 | ||||
| Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking) | | ||||
| Nick Harland (Corporate Broking) | |||||
| | | ||||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com | ||||
| Anna Dunphy /Phillip Marriage | Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082 | ||||
About Polarean (www.polarean.com)
Polarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW™, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
